Notícias

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

Novo Nordisk A/S (NYSE:NVO) is one of the best low volatility stocks to buy under $50. Novo Nordisk A/S (NYSE:NVO) announced on June 11 that the Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The […]

Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.

Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how much the Novo deal is helping demand.

Novo Nordisk (CPSE:NOVO B) received UK approval for an oral version of Wegovy, the first authorized daily GLP-1 pill for weight management. The authorization covers obesity and overweight adults, offering an alternative to injectable GLP-1 therapies. The decision is expected to influence how obesity is treated in primary care and specialist settings across the UK. Retailers and consumer companies are already tracking GLP-1 use as they assess shifts in spending on food, fitness, and wellness...

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.

Shell, Novo, SAP, Rave and Vaso are included in this Analyst Blog.

These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.

Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”

Shell, Novo Nordisk and SAP headline Zacks' top research reports, highlighting growth drivers, guidance outlooks and key risks shaping performance.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best weight loss drugs on this list. TheFly reported on June 17 that Barclays maintained its Overweight rating on HIMS while increasing its price target to $39.00 from $29.00. The […]

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Novo Nordisk A/S (NYSE:NVO) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Berenberg increased its price target for NVO shares to DKK 325 from DKK 300 while maintaining its Buy rating […]

Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.

Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.

The rally reflects broader positive sentiment toward Viking’s lead candidate, VK2735, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms for obesity.

Novo Nordisk A/S (NYSE:NVO) is among the Best Pharmaceutical Stocks. On June 19, Novo Nordisk A/S (NYSE:NVO)’s primary owner, the Novo Nordisk Foundation, reported that it is launching research incubators across Europe to speed up obesity and diabetes drug development. The foundation said it is funding a pan-European program targeting cardiometabolic diseases. It will commit up […]

Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The company has entered into a partnership with Novo Nordisk to provide access to medications such as Wegovy and Ozempic. Hims & Hers Health is extending its international reach through the acquisition of Eucalyptus. Hims & Hers Health, best known for its direct-to-consumer telehealth services, is moving deeper into prescription weight management at a time...

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

European equities traded in the US as American depositary receipts started the week higher late Mond

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

The package delivery giant is building out 27 temperature-controlled facilities across three continents as demand for refrigerated pharmaceuticals grows

With a short percentage of shares outstanding of 0.51%, Novo Nordisk A/S (NYSE:NVO) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares. Earlier, on […]

UK GLP-1 users are shifting spending toward high-protein foods, vitamins and fitness products.

F5 surged after a Zacks Rank upgrade, while Atlanticus and Starbucks posted notable gains as several Zacks strategies outperformed.

The approval of the first oral pill this month will drive a more powerful shift in consumer habits, PwC found in a study.

Novo Nordisk A/S is investigating claims by cyber extortion group FulcrumSec, which alleges it stole more than a terabyte of data from the pharmaceutical company and is considering selling portions of the information after an unsuccessful $25 million ransom demand. FulcrumSec Claims Months-Long Access To Company Systems Citing a message posted by FulcrumSec on Tuesday, Reuters reported that the group spent more than two months inside Novo Nordisk’s networks collecting data. The hackers claimed t